Imperial College London

MrNicholasJohnson

Faculty of MedicineSchool of Public Health

Clinical Trials Statistician
 
 
 
//

Contact

 

+44 (0)20 7594 1751nicholas.johnson

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Summary

Nicholas Johnson is a Clinical Trials Statistician at Imperial Clinical Trials Unit (ICTU), School of Public Health with over 6 years experience in clinical trials.

Whilst primarily part of the Cardiovascular/Respiratory trial team, he has worked on studies across a number of therapeutic areas. He has also had experience in Phase 1 Pharmacokinetic (PK) analysis. Current studies include; HOPE-HF, DeVENT, MALIBO and RIO whilst past studies include AVATAR-AF, Endobarrier and SERCA-LVAD.

Nicholas completed his BSc in Statistics and Computing from the Open University in 2011 and subsequently obtained an MSc (Merit) in Statistics from the University of Kent in 2013.

A keen runner and cat-lover, Nicholas has been with ICTU since October 2015.

Publications

Journals

Glaysher M, Ward J, Aldhwayan M, et al., 2021, The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids, Clinical Nutrition, Vol:40, ISSN:0261-5614, Pages:2343-2354

Ruban A, Glaysher MA, Miras AD, et al., 2020, A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT, Efficacy and Mechanism Evaluation, Vol:7, ISSN:2050-4365, Pages:1-130

Lyon A, Babalis D, Morley-Smith AC, et al., 2020, Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL, Gene Therapy, Vol:27, ISSN:0969-7128, Pages:579-590

Cro S, Forbes G, Johnson NA, et al., 2020, Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomized trials, Bmc Medicine, Vol:18, ISSN:1741-7015

Conference

Ruban A, Glaysher M, Miras A, et al., 2020, ONE YEAR OF DUODENAL-JEJUNAL BYPASS LINER THERAPY (ENDOBARRIER (R)) LEADS TO SIGNIFICANT CHANGES IN LIVER BIOCHEMISTRY ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE, GI Fellows Sessions at Digestive Disease Week / 61st Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract, MOSBY-ELSEVIER, Pages:AB225-AB226, ISSN:0016-5107

More Publications